Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

TAKHZYRO

LANADELUMAB-FLYO

Standard Dose
300MG/2ML (150MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview TAKHZYRO is listed in Drugs@FDA under application 761090 (BLA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient LANADELUMAB-FLYO Form and strength SOLUTION;SUBCUTANEOUS - 300MG/2ML (150MG/ML) Sponsor DYAX CORP.

Structured Monograph

Clinical summary

Approval overview TAKHZYRO is listed in Drugs@FDA under application 761090 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient LANADELUMAB-FLYO Form and strength SOLUTION;SUBCUTANEOUS - 300MG/2ML (150MG/ML) Sponsor DYAX CORP. Submission history Latest submission status date: 2023-02-03 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.